Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression

@article{Thein2008EstimationOS,
  title={Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression},
  author={Hla-Hla Thein and Qi-long Yi and Gregory J. Dore and Murray Krahn},
  journal={Hepatology},
  year={2008},
  volume={48}
}
Published estimates of liver fibrosis progression in individuals with chronic hepatitis C virus (HCV) infection are heterogeneous. We aimed to estimate stage‐specific fibrosis progression rates and their determinants in these individuals. A systematic review of published prognostic studies was undertaken. Study inclusion criteria were as follows: (1) presence of HCV infection determined by serological assays; (2) available information about age at assessment of liver disease or HCV acquisition… Expand
Role of Hepatitis C virus genotype 3 in liver fibrosis progression – a systematic review and meta‐analysis
TLDR
Viral genotype 3 was associated with faster fibrosis progression in single‐biopsy studies, but the association was not significant in paired biopsies studies, although the latter may be limited by important indication bias, short observation time and small sample size. Expand
Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update
TLDR
Findings indicate that FPRs display substantial heterogeneity across study populations and pooled values from more homogenous subpopulations should be considered when estimating prognosis, and should be a valuable resource for patients, clinicians and clinical policymakers. Expand
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C.
TLDR
This study shows a significant association of genotype 3 with accelerated fibrosis using both stage-constant and stage-specific estimates of fibrosis progression rates. Expand
The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression.
TLDR
Analysis of aggregate level data suggests that for patients who contracted HCV through injection drug use prognosis is poor in populations with many male patients and high levels of alcohol consumption. Expand
The goal of therapy is to prevent complications and death from chronic viral hepatitis [2,4]. Because of the slow evolution of chronic hepatitis over sev-
Background: Liver biopsy and virological end points are standard references for assessing the effect of viral hepatitis treatments. We aimed to review evidence-based published data of biomarkers thatExpand
Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.
TLDR
Left untreated, PWID with chronic HCV infection will develop liver sequelae (including HCC) in mid- to late-adulthood and scaling up of effective HCV prevention and early engagement in care and treatment will facilitate the elimination HCV as a source of serious disease in PWID. Expand
Prevalence of Cirrhosis in Hepatitis C Patients in the Chronic Hepatitis Cohort Study (CHeCS): A Retrospective and Prospective Observational Study
TLDR
It is suggested that cirrhosis in CHC patients may be significantly underdocumented and underdiagnosed, and ICD-9 codes may not be reliable as the sole indicator of the prevalence of cirrhotic disease in cohort studies. Expand
Prediction of Hepatic Fibrosis in Patients Coinfected With HIV and Hepatitis C Virus Based on Genetic Markers
TLDR
CRS itself seems not to be a good marker for identifying HIV/HCV-coinfected patients who are at high risk of developing liver fibrosis, however, CRS score coupled with clinical factors might help to distinguish between nonprogressors and progressors patients. Expand
Fibrosis Progression in Patients With Chronic Hepatitis C Virus Infection.
TLDR
Fibrosis progression in HCV is not linear but varies according to stage, with the highest progression in patients with the lowest fibrosis severity, and patients who experience flares in the ALT level are also more likely to progress. Expand
Hepatitis C Virus Disease Progression in People Who Inject Drugs: Protocol for a Systematic Review and Meta-Analysis
TLDR
This protocol describes the methods used for a systematic review and meta-analysis of published and unpublished data on the natural history of HCV among PWID including viral clearance, fibrosis progression, and the incidence of compensated cirrhosis, decompensated cirrhoses, hepatocellular carcinoma, and liver-related mortality. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 93 REFERENCES
Estimating progression to cirrhosis in chronic hepatitis C virus infection
TLDR
For persons who acquire HCV infection in young adulthood, less than 10% are estimated to develop cirrhosis within 20 years, suggesting community‐based cohort studies are likely to provide a more representative basis for estimating disease progression at a population level. Expand
Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment.
TLDR
Researchers using estimates of disease progression should be aware that the method of cohort recruitment has considerable influence on the progression rates that are derived. Expand
Progression of liver fibrosis among injection drug users with chronic hepatitis C
TLDR
In this setting with low fibrosis prevalence, FibroSURE, ALT, and APRI tests predict insignificant fibrosis; however, further work is needed to find noninvasive markers of significant liver fibrosis. Expand
Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study
TLDR
The overall rate of fibrosis progression in patients with hepatitis C was low but increased in patients who were older or had fibrosis on their index biopsy, suggesting that HCV infection will place an increasing burden on health care services in the next 20 years. Expand
Natural history of liver fibrosis progression in patients with chronic hepatitis C
TLDR
The host factors of ageing, alcohol consumption, and male sex have a stronger association with fibrosis progression than virological factors in HCV infection. Expand
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.
TLDR
In patients infected with hepatitis C, the majority of fibrosis progression occurred in those aged fifty years or older, and can be divided into four successive periods with very slow, slow, intermediate and rapid progression rates. Expand
Progression of liver fibrosis in blood donors infected with hepatitis C virus.
TLDR
This study suggests that RFP is extremely variable, it is exponential with age, and mainly influenced by host characteristics, especially age at contamination and possibly ethnical group. Expand
Severity and correlates of liver disease in hepatitis C virus–infected injection drug users
TLDR
Data indicate that severe liver disease is uncommon in this urban, HCV‐infected IDU cohort, especially in younger persons and those with repeatedly normal liver enzymes. Expand
Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.
TLDR
Interferon treatment changes the natural fibrosis progression rate in patients with chronic hepatitis C independently of genotype and early response, after genotype, viremia, sex, age at infection, duration of infection, and alcohol consumption were taken into account. Expand
Improving the accuracy of long‐term prognostic estimates in hepatitis C virus infection
TLDR
Application of the Markov maximum likelihood method allows accurate estimation of stage‐specific transition probabilities from the many studies in which only a single biopsy is available and supports the hypothesis that rates of fibrosis vary between stages. Expand
...
1
2
3
4
5
...